Trial Profile
Real Situation Observational Study of Viraferonpeg [peginterferon-alfa-2b] in Patients With Chronic Hepatitis C
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms ADEQUATION
- Sponsors Merck Sharp & Dohme Corp.
- 25 Aug 2008 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
- 18 Jul 2008 New trial record.